{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:03:45Z","timestamp":1782975825802,"version":"3.54.5"},"reference-count":72,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Radiotherapy remains one of the contemporary cornerstones of cancer treatment in the neoadjuvant, curative, adjuvant and palliative settings, either in isolation or as a multimodal approach. Moreover, recent advances in targeted immune checkpoint therapy have firmly established immunotherapy as the fourth pillar in cancer therapy alongside surgery, chemotherapy and notably radiotherapy. There is emerging evidence to suggest both radioresistance and reduced efficacy of immune checkpoint blockade (ICB) are potentiated by the tumour microenvironment (TME) and in fact modulating aspects of this immunosuppressive milieu is instrumental to unlocking anti-tumour immunity. The response rates of Upper Gastrointestinal (UGI) malignancies to ICB remains modest at 10\u201315%, compared to melanoma at 20\u201340%. Harnessing the effects of radiotherapy through remodelling of the TME using ICB as a radiosensitisor is an avenue showing promise. Here we explore the rationale behind combining radiotherapy with ICB, as a symbiotic relationship in shifting the balance in favour of anti-tumour immunity. We discuss the effects of radiotherapy on immunogenic cell death, the concept of the abscopal effect, the importance of the cGAS STING pathway, and their relevance in the context of the tumour microenvironment. Furthermore, dosing and timing of radiotherapy and ICB is now being evaluated for its synergistic effects on host tumour immunity, and we review the ongoing efforts and current available literature for single agent and dual agent ICB in combination multimodal therapy for both locally advanced operable and metastatic disease of the upper gastrointestinal tract.<\/jats:p>","DOI":"10.3390\/ijms22031071","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T03:31:30Z","timestamp":1611286290000},"page":"1071","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-3896","authenticated-orcid":false,"given":"Noel E.","family":"Donlon","sequence":"first","affiliation":[{"name":"Department of Surgery, School of Medicine, Trinity College Dublin, Dublin 8, Ireland"},{"name":"Trinity St James\u2019 Cancer Institute, St James\u2019s Hospital Dublin, Dublin 8, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1883-7875","authenticated-orcid":false,"given":"Robert","family":"Power","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Trinity College Dublin, Dublin 8, Ireland"},{"name":"Trinity St James\u2019 Cancer Institute, St James\u2019s Hospital Dublin, Dublin 8, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conall","family":"Hayes","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Trinity College Dublin, Dublin 8, Ireland"},{"name":"Trinity St James\u2019 Cancer Institute, St James\u2019s Hospital Dublin, Dublin 8, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Davern","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Trinity College Dublin, Dublin 8, Ireland"},{"name":"Trinity St James\u2019 Cancer Institute, St James\u2019s Hospital Dublin, Dublin 8, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Trinity College Dublin, Dublin 8, Ireland"},{"name":"Trinity St James\u2019 Cancer Institute, St James\u2019s Hospital Dublin, Dublin 8, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Lysaght","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Trinity College Dublin, Dublin 8, Ireland"},{"name":"Trinity St James\u2019 Cancer Institute, St James\u2019s Hospital Dublin, Dublin 8, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: Recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e031434","DOI":"10.1136\/bmjopen-2019-031434","article-title":"The Upper Gastrointestinal Cancer Registry (UGICR): A clinical quality registry to monitor and improve care in upper gastrointestinal cancers","volume":"9","author":"Maharaj","year":"2019","journal-title":"BMJ Open"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MOG.0000000000000542","article-title":"The emerging role of immunotherapy for esophageal cancer","volume":"35","author":"Kelly","year":"2019","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7150\/ijms.3635","article-title":"Cancer and radiation therapy: Current advances and future directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int. J. Med. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17048","DOI":"10.1038\/nrdp.2017.48","article-title":"Oesophageal cancer","volume":"3","author":"Smyth","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3389\/fimmu.2020.00223","article-title":"Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy","volume":"11","author":"Zemek","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"McBride, S., Sherman, E., Tsai, C.J., Baxi, S., Aghalar, J., Eng, J., Zhi, W.I., McFarland, D., Young, R., and Lefkowitz, R. (2020). Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. J. Clin. Oncol.","DOI":"10.1200\/JCO.20.00290"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","article-title":"PD-1 Restrains Radiotherapy-Induced Abscopal Effect","volume":"3","author":"Park","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9548","DOI":"10.1200\/JCO.2020.38.15_suppl.9548","article-title":"Radiotherapy to augment pembrolizumab responses and outcomes in metastatic non-small cell lung cancer: Pooled analysis of two randomized trials","volume":"38","author":"Welsh","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jcp.25048","article-title":"Mechanisms and Consequences of Double-Strand DNA Break Formation in Chromatin","volume":"231","author":"Cannan","year":"2016","journal-title":"J. Cell Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature23470","article-title":"Mitotic progression following DNA damage enables pattern recognition within micronuclei","volume":"548","author":"Harding","year":"2017","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal. Transduct Target. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nature12640","article-title":"Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP","volume":"503","author":"Ablasser","year":"2013","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41467-017-01566-5","article-title":"Host STING-dependent MDSC mobilization drives extrinsic radiation resistance","volume":"8","author":"Liang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fonc.2018.00322","article-title":"Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance","volume":"8","author":"Budhwani","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"63ra94","DOI":"10.1126\/scitranslmed.3001375","article-title":"Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47","volume":"2","author":"Chao","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","article-title":"ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment","volume":"25","author":"Dillon","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sharma, A., Bode, B., Wenger, R.H., Lehmann, K., Sartori, A.A., Moch, H., Knuth, A., von Boehmer, L., and van den Broek, M. (2011). \u03b3-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028217"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","article-title":"Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Arneth, B. (2019). Tumor Microenvironment. Medicina, 56.","DOI":"10.3390\/medicina56010015"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1172\/JCI61931","article-title":"Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects","volume":"122","author":"Ruocco","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"86522","DOI":"10.18632\/oncotarget.13287","article-title":"Increasing the efficacy of radiotherapy by modulating the CCR2\/CCR5 chemokine axes","volume":"7","author":"Connolly","year":"2016","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS(+)\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1204506","DOI":"10.1080\/2162402X.2016.1204506","article-title":"Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection","volume":"5","author":"Sektioglu","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression\u2014Implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/2326-6066.CIR-18-0633","article-title":"CCR2-Dependent Recruitment of Tregs and Monocytes Following Radiotherapy Is Associated with TNFalpha-Mediated Resistance","volume":"7","author":"Mondini","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-Derived Suppressor Cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1118\/1.3639137","article-title":"Tumor hypoxia is an important mechanism of radioresistance in hypofractionated radiotherapy and must be considered in the treatment planning process","volume":"38","author":"Carlson","year":"2011","journal-title":"Med. Phys."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-12-0858","article-title":"Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy","volume":"18","author":"Meijer","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cmet.2016.10.015","article-title":"Lactate Wreaks Havoc on Tumor-Infiltrating T and NK Cells","volume":"24","author":"Scott","year":"2016","journal-title":"Cell Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1172\/JCI96582","article-title":"Increased vessel perfusion predicts the efficacy of immune checkpoint blockade","volume":"128","author":"Zheng","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm0498-408","article-title":"Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma","volume":"4","author":"Yilmaz","year":"1998","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538\u201312, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1200\/JCO.2019.37.4_suppl.2","article-title":"Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study","volume":"37","author":"Kojima","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S1192","DOI":"10.1016\/j.annonc.2020.08.2298","article-title":"LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study","volume":"31","author":"Kato","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S1191","DOI":"10.1016\/j.annonc.2020.08.2296","article-title":"LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer (GC\/GEJC)\/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study","volume":"31","author":"Moehler","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184\u2013043): A multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: A beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clon.2019.01.010","article-title":"Hypofractionated Radiotherapy in Oesophageal Cancer for Patients Unfit for Systemic Therapy: A Retrospective Single-Centre Analysis","volume":"31","author":"Jones","year":"2019","journal-title":"Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3389\/fmed.2019.00244","article-title":"Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?","volume":"6","author":"Spaas","year":"2019","journal-title":"Front. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.4049\/jimmunol.170.12.6338","article-title":"Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy","volume":"170","author":"Chakraborty","year":"2003","journal-title":"J. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Alard","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ijrobp.2018.06.404","article-title":"Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer","volume":"102","author":"Colbert","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/j.ijrobp.2017.06.303","article-title":"Combined Immune Checkpoint Blockade and Radiation Therapy: Timing and Dose Fractionation Associated with Greatest Survival Duration Among Over 750 Treated Patients","volume":"99","author":"Samstein","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","article-title":"A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors","volume":"123","author":"Venkatesulu","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40425-016-0149-6","article-title":"A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"4","author":"Crocenzi","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","article-title":"Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Cancer","volume":"94","author":"Wild","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1701737","DOI":"10.1183\/13993003.01737-2017","article-title":"Immunotherapy and pulmonary toxicities: Can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?","volume":"51","author":"Louvel","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3389\/fonc.2020.00891","article-title":"The Cancer-Immune Set Point in Oesophageal Cancer","volume":"10","author":"Power","year":"2020","journal-title":"Front. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/3\/1071\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:13:49Z","timestamp":1760159629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/3\/1071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":72,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ijms22031071"],"URL":"https:\/\/doi.org\/10.3390\/ijms22031071","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]}}}